



PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/037,480	
			Filing Date	January 4, 2002	
			First Named Inventor	Gregor Cevc	
			Art Unit	1797	
			Examiner Name	Ana M. Fortuna	
Sheet	1	Of	6	Attorney Docket Number	35946-703.301

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 20070042030 A1	02/22/2007	Cevc	
	2.	US 4,731,210	03/15/1988	Weder et al.	
	3.	US 4,937,182	06/26/1990	Hancock et al.	
	4.	US 5,244,678	09/14/1993	Legros et al.	
	5.	US 5,614,178	03/25/1997	Bloom et al.	
	6.	US 5,648,095	07/15/1997	Ilium et al.	
	7.	US 5,681,849	10/08/1997	Richter et al.	
	8.	US 5,874,095	02/23/1999	Deckner et al.	
	9.	US 6,193,996	02/27/2001	Effing et al.	
	10.	US 6,200,598	03/13/2001	Needham	
	11.	US 6,248,353	06/19/2001	Singh	
	12.	US 6,277,892	08/21/2001	Deckner et al.	
	13.	US 6,645,529 A1	11/11/2003	Gergely et al.	
	14.	US 6,726,598	04/27/2004	Jarvis et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	15.	EP 0582239 (with English abstract)	02/09/1994	RHONE-POULENC RORER GMBH		
	16.	EP 1031346	05/02/2002	IDEA AG		
	17.	EP 1031347	04/17/2002	IDEA AG		
	18.	JP 2006131597 (with English abstract)	05/02/2006	Hisamitsu Pharmaceut CO inc		
	19.	WO 90/09385	08/23/1990	The Liposome Company Inc		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/037,480	
				Filing Date	January 4, 2002	
				First Named Inventor	Gregor Cevc	
				Art Unit	1797	
				Examiner Name	Ana M. Fortuna	
Sheet	2	Of	6	Attorney Docket Number		35946-703.301

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	20.	WO 91/01146	02/07/1991	Praxis Biolog Inc		
	21.	WO 92/04009	03/19/1992	Univ London Pharmacy		
	22.	WO 95/35095	12/28/1995	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM		
	23.	WO 98/24407	06/11/1998	L'Oreal		
	24.	WO 01/000247	01/04/2001	The Liposome Company, Inc		
	25.	WO 01/01962	01/11/2001	IDEA Innovative GmBh		
	26.	WO 00/00597	01/06/2000	The University of Manitoba		
	27.	WO 00/44349	08/03/2000	IDEA AG		
	28.	WO 02/058670	08/01/2002	CHASIN, et al		
	29.	WO 02/32398	04/25/2002	KOHANE, et al		
	30.	WO 04/032900	04/22/2004	IDEA AG		
	31.	WO 05/063213	07/14/2005	Biodelivery Sciences International, Inc		
	32.	WO 06/050926	05/18/2006	IDEA AG		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/037,480
				Filing Date	January 4, 2002
				First Named Inventor	Gregor Cevc
				Art Unit	1797
				Examiner Name	Ana M. Fortuna
Sheet	3	Of	6	Attorney Docket Number	35946-703.301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	33.	Almeida, et al. "Nasal delivery of vaccines," Journal of Drug Targeting, Vol 3, No 6, pp. 455-67 (1996).	
	34.	Byas-Smith, et al. "Transdermal clonidine compared to placebo in painful diabetic neuropathy using two stage 'enriched enrollment' design," Pain, Vol 60, pp. 267-274 (1995).	
	35.	Carafa, et al. "Lidocaine-loaded Non-ionic Surfactant Vesicles: Characterization and In Vitro Permeation Studies," International Journal of Pharmaceutics 231:21-32. (2002).	
	36.	Castillo, et al. "Glucocorticoids Prolong Rat Sciatic Nerve Blockade In Vivo from Bupivacaine Microspheres," Anesthesiology, Vol 85, No 5, pp. 1157-66 (1996).	
	37.	Cevc, et al. "Phospholipids handbook", Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 375-376 and 404 (1993).	
	38.	Cevc, et al. "New, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes, " Biochemica et Biophysica Acta 1514 (2001) 191-205.	
	39.	Claims filed February 26, 2007, in connection with U.S. Patent Application No. 10/984,450 (U.S. Patent Publication No US 2005/0123897 a1), under examination by Examiner Fortuna of the USPTO.	
	40.	Claims filed February 4, 2003, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
	41.	Claims filed May 12, 2004, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1), under examination by Examiner Ghali of the USPTO.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/037,480
				Filing Date	January 4, 2002
				First Named Inventor	Gregor Cevc
				Art Unit	1797
				Examiner Name	Ana M. Fortuna
Sheet	4	Of	6	Attorney Docket Number	35946-703.301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	42.	Claims filed May 31, 2005, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO.	
	43.	Claims filed May 31, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), Under examination by Examiner Fortuna of the USPTO.	
	44.	Claims filed October 20, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
	45.	Claims filed October 31, 2007, in connection with U.S. Patent Application No. 10/984,450 (U.S. Patent Publication No. US 2005/0123897 A1), under examination by Examiner Ana M. Fortuna of the USPTO.	
	46.	Claims presently pending in U.S. Patent Application No 09/890,335, under examination by Examiner Gangle of the USPTO.	
	47.	Claims presently pending in U.S. Patent Application No 09/890,371, under examination by Examiner Hissong of the USPTO.	
	48.	Copy of International Search Report for International Patent Application No. PCT/EP2005/011986. (July 4, 2006).	
	49.	Definition of Microbicide, Wikipedia, The Free Online encyclopedia (2007).	
	50.	Frantzen et al. " Assessing the accuracy of routine Photon Correlation Spectroscopy Analysis of Heterogeneous Size Distributions," AAPS PharmSciTech, Vol 4, No 3, Article 36, pp. 1-9 (2003).	
	51.	Friedrich, et al. "Physicochemical Characterization of a Reverse Micellar Solution after Loading with Different Drugs," Pharmazie 55 (2000) 10, 755-758.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/037,480
				Filing Date	January 4, 2002
				First Named Inventor	Gregor Cevc
				Art Unit	1797
				Examiner Name	Ana M. Fortuna
Sheet	5	Of	6	Attorney Docket Number	35946-703.301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	52.	Glen, et al. "Skin immunization made possible by cholera toxin 'letter'", Nature, GB, MacMillan Journal LTD., London, Vol 391, no 6670, pp. 851 (Feb 1998)	
	53.	Grahame, R. "Transdermal non-steroidal anti-inflammatory agents," BJCP, Vol 49, Nol , pp. 33-35 (Jan-Feb 1995).	
	54.	Holzbach, RT. "Detection of Vesicles in native and model Biles by Morphological and other structural Techniques: applications and limitations," Hepatology, Sep12 (3 Pt 2), pp. 106S- 112S (1990).	
	55.	Lehmann, et al. "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn." Journal of the European Academy of Dermatology and Venereology, 18(S2):167- 168. (October 2004).	
	56.	Merck Index: 10th Edition. pp. 779-780. (1983).	
	57.	Office Action issued December 28, 2006, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. 2004/0105881 A1) under examination by Examiner Ghali of the USPTO.	
	58.	Office Action issued May 30, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
	59.	Office Action issued on August 28, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by the Examiner Fortuna of the USPTO	
	60.	Office Action issued on February 7, 2006, in connection with U.S. Patent Application No 10/984,450 (U.S. Patent Publication No US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO.	
	61.	Paul, et al. "Non Invasive administration of protein antigens: transdermal immunization with bovine serum albumin in transfersomes," Vaccine Research, Vol 4, No 3, pp. 145-	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/037,480
				Filing Date	January 4, 2002
				First Named Inventor	Gregor Cevc
				Art Unit	1797
				Examiner Name	Ana M. Fortuna
Sheet	6	Of	6	Attorney Docket Number	35946-703.301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		164 (1995).	
	62.	Paul, et al. "Transdermal Immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carders, transfersomes," Vaccine, Vol 16, No 2-3, pp. 188-195 (Jan 1998).	
	63.	Pending Claims of U.S. Application No. 11/634,091 (Unpublished).	
	64.	Product Information, "Polysorbate 80 VG" (2004).	
	65.	Product Information, "Tween 80 Pure" (2004).	
	66.	Ranade, V. "Drug Delivery Systems.6. Transdermal Drug Delivery," J. Clin Pharmacol, Vol 31, pp. 401-418 (1991).	
	67.	Trotta, et al. "Deformable liposomes for dermal administration of methotrexate." International Journal of Pharmaceutics, 270:119-125. (February 11, 2004).	
	68.	Trotta, et al. "Elastic liposomes for skin delivery of dipotassium glycyrrhizinate." International Journal of Pharmaceutics, 241(2):319-327. (July 25, 2002).	
	69.	Valenta, et al. "Evaluation Of Novel Soya-lecithin Formulations for Dermal use containing Ketoprofen as a Model Drug," Journal of Controlled Release 63 (2000) 165-173.	
	70.	Wess, L. "Down, down, deeper and down." Biocentury, The Bernstein Report on BioBusiness, 12(22):A11-A12. (May 17, 2004).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.